Literature DB >> 19386019

Off-label use in dermatology in Germany: what has changed since 2004.

Norbert H Brockmeyer1, Ulrike Brucklacher, Anja Potthoff, Stefanie Reich-Schupke.   

Abstract

Off-label use is defined as the usage of pharmaceuticals beyond their submitted, tested and approved use. Not only indications but also doses, route of administration, patients' characteristics and concomitant therapies are affected by the approval. In recent years, the impact of off-label use has increased markedly primarily because of the large number of new medications with often limited approval. In dermatology, a multitude of diagnoses exist which are so uncommon that they have no chance of approval studies. Experiences of off-label use often provide important scientific data that can influence or even improve further concepts of therapy. Both professional liability and mode of payment are still controversial for medications in off-label use. There is an urgent need for more legal certainty in use of off-label medication to guarantee maximum safety for patients and medical staff. Both professional societies and funding agencies should work together to resolve this problem.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19386019     DOI: 10.1111/j.1610-0387.2009.07084.x

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  2 in total

1.  [Off-label use and G-BA. Legal framework for off-label use].

Authors:  U Brucklacher; N H Brockmeyer; C Riedel
Journal:  Hautarzt       Date:  2013-10       Impact factor: 0.751

2.  [Appropriate off-label prescription in practice].

Authors:  M Augustin
Journal:  Hautarzt       Date:  2013-10       Impact factor: 0.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.